
Vertical integration in the pharmaceutical industry refers to the consolidation of different stages of the supply chain under one company's control. This can include manufacturing, distribution, and sales.
For example, a company like CVS Health has vertically integrated by acquiring several distribution and logistics companies, allowing them to control the entire supply chain.
This integration can lead to increased efficiency and cost savings, but it can also limit competition and stifle innovation.
Additional reading: Multan Electric Power Company
Vertical Integration in Drug Channels
Vertical integration in the drug channels industry has been a topic of debate, with some arguing it can help reduce healthcare costs, while others raise concerns about anti-competitive behavior.
The Drug Channels Institute has released an updated analysis highlighting the major business relationships among the largest companies in the sectors, including insurers, Pharmacy Benefit Managers (PBMs), specialty pharmacies, and healthcare services.
Hospitals are increasingly relying on external companies to manage their specialty pharmacies, with over one-third using an external company for specialty pharmacy services and/or to provide specialty medications. This arrangement allows hospitals to reduce costs and risks associated with launching and operating an in-house specialty pharmacy.
Broaden your view: Lists of Distribution Companies
Some of the largest companies partnering with hospitals and health systems for specialty pharmacy services include Shields Health Solutions and Trellis Rx. These partnerships often involve hospitals owning the pharmacies, while private companies earn fees and a share of the profits for managing them.
Here are some of the strategies hospitals are using to profit from their specialty pharmacies:
- Directing employed physicians not to prescribe a new specialty drug unless the manufacturer adds the hospital's specialty pharmacy to its network.
- Demanding that payers include their in-house pharmacy as a preferred network option as part of their overall contracting.
- Using the 340B Drug Pricing Program to acquire discounted specialty drugs and dispense them from internal pharmacies.
The 340B program has incentivized hospitals to operate specialty pharmacies, with about 98% of respondents participating in the program. This has led to hospitals generating substantial profits by acquiring discounted specialty drugs and dispensing them from internal pharmacies.
Pharmaceutical Wholesalers' Role
Pharmaceutical wholesalers have strengthened their position in buy-and-bill channels for provider-administered drugs through vertical integration with their downstream customers.
Vertical integration has allowed wholesalers to gain more control over the supply chain and better serve their customers. This has helped them to increase their market share and profitability.
Private equity roll-up activity has provided wholesalers with strategic opportunities to acquire ownership stakes in practice management companies. This has given them access to valuable data and insights that can inform their business decisions.
Wholesalers are now more than just middlemen; they're partners in the healthcare supply chain. By integrating with downstream customers, they can offer more comprehensive services and solutions.
Vertical Integration Lessons
More than one-third of hospitals rely on external companies for specialty pharmacy services and/or to provide specialty medications. These external companies earn fees and a share of the profits for managing the pharmacies.
Hospitals can generate substantial profits by acquiring discounted specialty drugs and dispensing them from internal pharmacies through the 340B Drug Pricing Program. This program incentivizes hospitals to operate specialty pharmacies.
Hospitals also rely on 340B contract pharmacies to profit from prescriptions dispensed by external pharmacies in limited networks. Strategies used by payers, PBMs, and manufacturers have narrowed specialty drug channels.
Here are some strategies used by hospitals to navigate these challenges:
- Directing employed physicians not to prescribe a new specialty drug unless the manufacturer adds the hospital's specialty pharmacy to its network.
- Demanding that the hospital's pharmacy gain access to a manufacturer's limited dispensing network.
- Demanding that a payer include its in-house pharmacy as a preferred network option as part of its overall contracting.
These strategies can help hospitals to increase their profitability and maintain access to specialty medications for their patients.
PBMs and Contracting
PBMs and Contracting play a crucial role in the drug channels vertical integration. The changing legal environment in healthcare is affecting PBMs, with regulatory updates impacting their operations.
PBMs are navigating the 340B drug pricing program, which has significant implications for their business. The removal of the AMP Cap has led to a review of insulin and rebate practices.
Copay maximizer and patient assistance programs are becoming increasingly important in PBM contracting. These programs can help manage costs and ensure patient access to necessary medications.
Spread pricing is a major concern in the industry, and optimal PBM contracting and pricing strategies are being developed to combat it. This involves understanding the financial implications of biosimilars and specialty therapeutics.
The PBM-Payer partnership is being strengthened through cost management strategies. This includes developing an understanding of vertical integration and the consolidation of PBMs.
Here's a breakdown of the key factors affecting PBMs and Contracting:
Market Trends and Price Wars
As the pharmaceutical industry continues to evolve, market trends and price wars are becoming increasingly relevant.
The adoption of biosimilars, such as Amgen's Amjevita, has been slow, with IQVIA reporting almost no adoption as of mid-2023.
CVS Health has taken a bold step into the market by launching Cordavis, a subsidiary that will market a private label, low-list-price version of Sandoz' Hyrimoz.
The market is also seeing the emergence of unbranded, low wholesale acquisition cost (WAC) versions of biosimilars, such as Boehringer-Ingelheim's new launch.
These developments indicate that the industry is shifting towards more affordable options for patients, which could have a significant impact on the market as a whole.
Here are some key players and their strategies:
These market trends and price wars will likely continue to shape the pharmaceutical industry in the years to come.
Featured Images: pexels.com


